These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 26643086

  • 1. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
    Kolben T, Augustin D, Armbrust R, Kolben TM, Degenhardt T, Burgmann M, Goess C, Ditsch N, Kates R, Harbeck N, Wuerstlein R.
    Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086
    [Abstract] [Full Text] [Related]

  • 2. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C, Chemo-N 0 Study Group.
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [Abstract] [Full Text] [Related]

  • 3. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 4. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
    Viala M, Alexandre M, Thezenas S, Lamy PJ, Maran-Gonzalez A, Gutowski M, Colombo PE, Romieu G, Jacot W, Guiu S.
    Breast Cancer Res Treat; 2017 Oct 15; 165(3):611-621. PubMed ID: 28685212
    [Abstract] [Full Text] [Related]

  • 5. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N, Kates RE, Schmitt M.
    J Clin Oncol; 2002 Feb 15; 20(4):1000-7. PubMed ID: 11844823
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
    Vénat-Bouvet L, Fermeaux V, Leobon S, Saidi N, Monteil J, Mollard J, Aubard Y, Jammet I, Tubiana-Mathieu N.
    Anticancer Res; 2014 Mar 15; 34(3):1213-7. PubMed ID: 24596362
    [Abstract] [Full Text] [Related]

  • 7. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group.
    J Natl Cancer Inst; 2001 Jun 20; 93(12):913-20. PubMed ID: 11416112
    [Abstract] [Full Text] [Related]

  • 8. Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.
    Saadoun H, Lamy PJ, Thezenas S, Pouderoux S, Bibeau F, Montels F, Romieu G, Colombo PE, Gutowski M, Jacot W.
    Future Oncol; 2014 Feb 20; 10(2):195-209. PubMed ID: 24490606
    [Abstract] [Full Text] [Related]

  • 9. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P.
    Histol Histopathol; 2009 Jul 20; 24(7):869-77. PubMed ID: 19475533
    [Abstract] [Full Text] [Related]

  • 10. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 11. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N.
    Breast Cancer Res Treat; 2013 Apr 01; 138(3):839-50. PubMed ID: 23568480
    [Abstract] [Full Text] [Related]

  • 12. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Marguet S, Mazouni C, Ramaekers BL, Dunant A, Kates R, Jacobs VR, Joore MA, Harbeck N, Bonastre J.
    Eur J Cancer; 2016 Aug 01; 63():168-79. PubMed ID: 27322916
    [Abstract] [Full Text] [Related]

  • 13. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    Jevrić M, Matić IZ, Krivokuća A, Đorđić Crnogorac M, Besu I, Damjanović A, Branković-Magić M, Milovanović Z, Gavrilović D, Susnjar S, Kisić Tepavčević D, Stanojković T.
    BMC Cancer; 2019 Jan 15; 19(1):71. PubMed ID: 30646864
    [Abstract] [Full Text] [Related]

  • 14. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
    Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C.
    Clin Breast Cancer; 2002 Aug 15; 3(3):196-200. PubMed ID: 12196277
    [Abstract] [Full Text] [Related]

  • 15. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
    Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.
    J Natl Cancer Inst; 2002 Jan 16; 94(2):116-28. PubMed ID: 11792750
    [Abstract] [Full Text] [Related]

  • 16. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 16; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

  • 17. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
    Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA.
    Clin Breast Cancer; 2004 Dec 16; 5(5):348-52. PubMed ID: 15585071
    [Abstract] [Full Text] [Related]

  • 18. High levels of uPA and PAI-1 predict a good response to anthracyclines.
    Borstnar S, Sadikov A, Mozina B, Cufer T.
    Breast Cancer Res Treat; 2010 Jun 16; 121(3):615-24. PubMed ID: 20039121
    [Abstract] [Full Text] [Related]

  • 19. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
    Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M.
    Breast Cancer Res; 2014 Aug 22; 16(4):428. PubMed ID: 25677449
    [Abstract] [Full Text] [Related]

  • 20. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
    Rabi ZA, Todorović-Raković N, Vujasinović T, Milovanović J, Nikolić-Vukosavljević D.
    Cancer Biomark; 2015 Aug 22; 15(6):745-54. PubMed ID: 26406416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.